The nation of Zimbabwe has declined a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to the United States' demand for confidential data.
This rejection came to light after a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman later clarified that the United States was requesting genetic material for scientific study and profit while refused to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued talks to find a deal agreeable to all parties so the nation's vital HIV programme can proceed.
Wider Context
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
Based on statements, 16 African countries have so far signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be available to our citizens if a new health crisis arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks already established through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to manage future pandemics.
"This system is intended to ensure that when a nation provides its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We are open to further discussions with our US partners on how subsequent co-operation could be arranged in a way that honours the independence and dignity of each country."
Medical Community Response
A leading public health body stated it recognised the official position, but suggested that negotiations must proceed since a large portion of the nation's Aids initiatives were funded by international support.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," it commented.
The halted deal underscores the continuing tensions between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.